International Journal of Clinical Research
International Journal of Clinical Research. 2026; 10: (7) ; 10.12208/j.ijcr.20260339 .
总浏览量: 442
无锡市新吴区新瑞医院 江苏无锡
*通讯作者： 崔晓红,单位：无锡市新吴区新瑞医院 江苏无锡; ；
目的 进一步观察达格列净联合厄贝沙坦治疗2型糖尿病（T2DM）合并高血压的临床疗效，重点分析其对内脏脂肪指标及不良心血管事件的影响。方法 本研究于2024年8月至2025年8月开展，从同期院内收治的T2DM合并高血压患者中抽取样本，筛选人数90例，采用双色球分组法完成组间安排，每组归入45例。对照组采取常规降糖+厄贝沙坦治疗方案，实验组采取达格列净+厄贝沙坦治疗方案，比对整体治疗效果。结果 实验组腰围、腰臀比、内脏脂肪面积、空腹血糖、糖化血红蛋白、收缩压、舒张压均显著优于对照组（P＜0.05）；不良心血管事件发生率显低对照组，呈现4.44％：15.56％比例数值，形成明显优劣差异（P＜0.05）。结论 联合疗法可推荐为一线首选治疗方案。该方案不仅能有效改善内脏脂肪堆积、优化血糖、血压控制，还可显著降低不良心血管事件发生风险，值得推广。
Objective To further investigate the clinical efficacy of dapagliflozin combined with irbesartan in the treatment of type 2 diabetes mellitus (T2DM) complicated with hypertension, with a focus on analyzing its effects on visceral fat indices and adverse cardiovascular events. Methods This study was conducted from August 2024 to August 2025. A sample of 90 patients with T2DM complicated with hypertension admitted to the hospital during the same period was selected. Patients were assigned to groups using a two-color ball grouping method, with 45 cases per group. The control group received conventional hypoglycemic therapy plus irbesartan, while the experimental group received dapagliflozin plus irbesartan, and the overall therapeutic outcomes were compared. Results The experimental group showed significantly better outcomes than the control group in waist circumference, waist-to-hip ratio, visceral fat area, fasting blood glucose, glycated hemoglobin, systolic blood pressure, and diastolic blood pressure (P<0.05). The incidence of adverse cardiovascular events was markedly lower in the experimental group (4.44% vs. 15.56%), demonstrating a significant superiority (P<0.05). Conclusion The combination therapy can be recommended as a first-line treatment option. This regimen not only effectively improves visceral fat accumulation and optimizes glycemic and blood pressure control but also significantly reduces the risk of adverse cardiovascular events, making it worthy of promotion.
[1] 陈婉莲，许金坤，吴清香.达格列净联合厄贝沙坦治疗合并高血压糖尿病肾病疗效分析[J].糖尿病新世界，2024, 27 (05):167-170.
[2] 张伟杰.达格列净对不同体重指数老年2型糖尿病合并高血压患者心脏保护作用的效果[J].糖尿病新世界,2025, 28(13):98-101.
[3] 李素梅,马晓涛,许毅.沙库巴曲缬沙坦钠、达格列净联合非奈利酮治疗2型糖尿病肾病合并高血压的临床疗效观察[J].大理大学学报,2025,10(2):32-36.
[4] 许蔚强,陈瞳,张利方.达格列净对老年2型糖尿病肾病合并高血压患者同型半胱氨酸的影响及疗效分析[J].中华老年心脑血管病杂志,2024,26(5):508-512.
[5] 吕文旭,陈瞳,丁巍.达格列净对不同体质量指数老年2型糖尿病合并高血压患者的心脏保护作用[J].中华老年心脑血管病杂志,2024,26(4):389-394.
[6] 杨世诚,马玉凤,张鹏.达格列净对高血压合并2型糖尿病患者经皮冠脉介入术后造影剂肾病的影响[J].中华高血压杂志,2024,32(12):1134-1140.
[7] 李飒飒,叶贝贝,刘鑫.达格列净对2型糖尿病合并高血压病患者血压变异性和左心室质量指数作用的研究[J].中国药师,2023,26(12):413-419.
[8] 徐丽玲,兰小,黄剑良.厄贝沙坦联合氨氯地平对高血压合并2型糖尿病患者血压节律的影响[J].中国药物经济学,2025,20(8):57-61.
[9] Zelniker TA, Wiviott SD, Raz I, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes mellitus across the range of kidney function. Circulation, 2019,140 (11): 911-921.
[10] McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med, 2019,381 (21):1995-2008.
[11] Lytvyn Y, Feig DI, Lovshin JA, et al. Sodium-glucose cotransporter 2 inhibitors: cardiovascular and renal protection in hypertension and diabetes. Can J Cardiol, 2020,36 (5):689-701.